HP
HealthInvest Partners Portfolio holdings
AUM $234M
1-Year Return
10.88%
This Quarter Return
-4.85%
1 Year Return
+10.88%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$211M
AUM Growth
-$1.91M
(-0.9%)
Cap. Flow
+$16.5M
Cap. Flow
% of AUM
7.82%
Top 10 Holdings %
Top 10 Hldgs %
63.34%
Holding
39
New
3
Increased
22
Reduced
7
Closed
3
Top Buys
| 1 |
AbbVie
ABBV
|
+$8.15M |
| 2 |
Eli Lilly
LLY
|
+$5.03M |
| 3 |
Boston Scientific
BSX
|
+$4.31M |
| 4 |
Revolution Medicines
RVMD
|
+$2.68M |
| 5 |
Edwards Lifesciences
EW
|
+$2.36M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$7.39M |
| 2 |
Merck
MRK
|
+$4.82M |
| 3 |
Ionis Pharmaceuticals
IONS
|
+$3.31M |
| 4 |
Immunocore
IMCR
|
+$1.68M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$1.12M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$671B
| $28.7M | 13.6% |
37,068
+6,504
| +21% | +$5.03M |
|
2
UnitedHealth
UNH
$315B
| $17.9M | 8.48% |
35,202
-288
| -0.8% | -$146K |
|
|
3
AbbVie
ABBV
$384B
| $16M | 7.58% |
90,723
+46,237
| +104% | +$8.15M |
|
|
4
Boston Scientific
BSX
$148B
| $13.8M | 6.56% |
154,222
+48,050
| +45% | +$4.31M |
|
5
Thermo Fisher Scientific
TMO
$179B
| $12.9M | 6.13% |
24,896
+2,884
| +13% | +$1.5M |
|
|
6
Merck
MRK
$202B
| $10.4M | 4.93% |
105,727
-48,972
| -32% | -$4.82M |
|
7
Stryker
SYK
$144B
| $9.3M | 4.41% |
25,660
+2,200
| +9% | +$797K |
|
8
Neurocrine Biosciences
NBIX
$13.9B
| $9.29M | 4.41% |
67,763
+7,156
| +12% | +$981K |
|
9
Alkermes
ALKS
$4.38B
| $7.67M | 3.64% |
266,499
+29,889
| +13% | +$860K |
|
10
Vertex Pharmaceuticals
VRTX
$101B
| $7.6M | 3.6% |
22,257
+5,264
| +31% | +$1.8M |
|
11
Cencora
COR
$56.5B
| $7.31M | 3.47% |
32,553
-3,991
| -11% | -$897K |
|
12
Amgen
AMGN
$148B
| $7.11M | 3.37% |
27,414
-1,551
| -5% | -$402K |
|
|
ITCI
13
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $5.94M | 2.82% |
71,138
-13,440
| -16% | -$1.12M |
|
|
14
Edwards Lifesciences
EW
$44.6B
| $5.07M | 2.4% |
68,296
+31,791
| +87% | +$2.36M |
|
15
Mirum Pharmaceuticals
MIRM
$3.73B
| $4.81M | 2.28% |
116,692
-21,629
| -16% | -$891K |
|
16
DexCom
DXCM
$29.6B
| $4.68M | 2.22% |
60,057
+6,300
| +12% | +$491K |
|
17
Harmony Biosciences
HRMY
$1.87B
| $4.1M | 1.95% |
120,501
-31,374
| -21% | -$1.07M |
|
18
Cardinal Health
CAH
$35.9B
| $3.62M | 1.72% |
30,680
+3,180
| +12% | +$375K |
|
19
NewAmsterdam Pharma
NAMS
$2.72B
| $3.56M | 1.69% |
138,983
| – | – |
|
20
Arcellx
ACLX
$4.17B
| $3.3M | 1.56% |
42,071
+1,841
| +5% | +$144K |
|
21
UFP Technologies
UFPT
$1.57B
| $3.17M | 1.5% |
23,159
+5,111
| +28% | +$699K |
|
22
Amicus Therapeutics
FOLD
$2.38B
| $3.08M | 1.46% |
326,840
+51,368
| +19% | +$483K |
|
23
BridgeBio Pharma
BBIO
$9.84B
| $2.81M | 1.34% |
103,032
+49,600
| +93% | +$1.36M |
|
|
24
Revolution Medicines
RVMD
$8.64B
| $2.68M | 1.27% |
+62,161
| New | +$2.68M |
|
25
Merus
MRUS
$5.15B
| $2.62M | 1.24% |
62,521
+11,834
| +23% | +$496K |
|